CF
BCTX

Cantor Fitzgerald’s Briacell Therapeutics BCTX Stock Holding History

Cantor Fitzgerald’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-373
Closed -$31.6K – 332
2024
Q4 		$31.6K Buy
+373
New +$44.7K ﹤0.01% 234

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Cantor Fitzgerald's BCTX Position: Q1 2025 in Review

Cantor Fitzgerald sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 373 shares — an estimated $31.6K sold.

Cantor Fitzgerald first reported a position in BCTX in Q4 2024 and held it in 1 quarter. The position peaked at $31.6K in Q4 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Cantor Fitzgerald reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 373 Briacell Therapeutics shares in Q1 2025, an estimated $31.6K.
  • Cantor Fitzgerald first reported a position in Briacell Therapeutics in Q4 2024 and held it in 1 quarter.
  • Cantor Fitzgerald's Briacell Therapeutics position peaked at $31.6K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Cantor Fitzgerald's 13F filing for Q1 2025, filed 15 May 2025.